专栏新型冠状病毒

AstraZeneca and the lessons of vaccine hesitancy

Trust must be restored in the only jab that is offered at cost

In a first edition of Edward Jenner’s 1798 book Vaccination Against Smallpox, where the English physician described the science behind the vaccine that would eventually eradicate the disease, a sceptical reader had scrawled, “Bah Humbug!!”

Vaccine hesitancy is nothing new. It predates the internet’s conspiracy-amplifying powers. And it certainly predates the technical, regulatory and political blunders that have undermined confidence in the Oxford/AstraZeneca Covid-19 vaccine in Europe and elsewhere. Mistrust more than misunderstanding stokes vaccine fear. The idea that confidence can be restored through “education” misses what we all know about trust: it is hard to gain and easy to lose.

The rollout of the AstraZeneca jab has appeared designed to shake faith in what is, almost certainly, an excellent vaccine. That is a calamity, especially for the developing world where — cheap, scaleable and easy to store — it was expected to be a global workhorse.

您已阅读21%(962字),剩余79%(3637字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

戴维•皮林

戴维•皮林(David Pilling)现为《金融时报》非洲事务主编。此前他是FT亚洲版主编。他的专栏涉及到商业、投资、政治和manbetx20客户端下载 方面的话题。皮林1990年加入FT。他曾经在伦敦、智利、阿根廷工作过。在成为亚洲版主编之前,他担任FT东京分社社长。

相关文章

相关话题

设置字号×
最小
较小
默认
较大
最大
分享×